Evidence map›Paper›PMID 35178861›Full record

ArticleESC heart failure2022

Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis.

Kathleen Pappritz, Jie Lin, Muhammad El-Shafeey, Henry Fechner, Uwe Kühl, Alessio Alogna, Frank Spillmann, Ahmed Elsanhoury, Rainer Schulz, Carsten Tschöpe and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Deep insight into cytokine storm: from pathogenesis to treatment.Signal transduction and targeted therapy · 2025
    Review
  19. Article
  20. [Colchicine-Phoenix from the ashes].Wiener klinische Wochenschrift · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Kathleen PappritzBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité, Universitätmedizin Berlin, Berlin, Germany.
Jie LinBerlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK), Berlin, Germany.
Muhammad El-ShafeeyBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité, Universitätmedizin Berlin, Berlin, Germany.
Henry FechnerDepartment of Applied Biochemistry, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
Uwe KühlDepartment of Cardiology, Charité - Universitätsmedizin Berlin, CVK, Berlin, Germany.
Alessio AlognaDepartment of Cardiology, Charité - Universitätsmedizin Berlin, CVK, Berlin, Germany.
Frank SpillmannDepartment of Cardiology, Charité - Universitätsmedizin Berlin, CVK, Berlin, Germany.
Ahmed ElsanhouryBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité, Universitätmedizin Berlin, Berlin, Germany.
Rainer SchulzPhysiologisches Institut, Fachbereich Medizin der Justus-Liebig-Universität, Giessen, Germany.
Carsten TschöpeBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité, Universitätmedizin Berlin, Berlin, Germany.
Sophie Van LinthoutBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité, Universitätmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEGerman Centre for Cardiovascular Research · DEJustus-Liebig-Universität Gießen · DEBerlin-Brandenburger Centrum für Regenerative Therapien · DETechnische Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe acute phase of a coxsackievirus 3 (CVB3)-induced myocarditis involves direct toxic cardiac effects and the systemic activation of the immune system, including the cardiosplenic axis. Consequently, the nucleotide-binding oligomerization domain-like receptor pyrin domain-containing-3 (NLRP3) inflammasome pathway is activated, which plays a role in disease pathogenesis and progression. The anti-inflammatory drug colchicine exerts its effects, in part, via reducing NLRP3 activity, and has been shown to improve several cardiac diseases, including acute coronary syndrome and pericarditis. The aim of the present study was to evaluate the potential of colchicine to improve experimental CVB3-induced myocarditis. METHODS AND

resultsC57BL6/j mice were intraperitoneally injected with 1 × 10

conclusionsColchicine improves LV function in CVB3-induced myocarditis, involving a decrease in cardiac and splenic NLRP3 inflammasome activity, without exacerbation of CVB3 load.

Indexed as

InflammasomesMyocarditisAnimalsColchicineDisease ProgressionHumansMiceNLR Family, Pyrin Domain-Containing 3 ProteinColchicineInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseCardiosplenic axisColchicineCoxsackievirus B3InflammationMyocarditis

Identifiers

PMID35178861
PMCPMC8934990
OpenAlexW4213186208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.